About Clean Cells
Clean Cells was created by three researchers, who were awarded the Aventis Foundation – “Institut de France” in 2000. By taking advantage of the growing market, this was the initiation of a platform of biological tests for safety testing. With traceability at the heart of our business, a quality approach was implemented in 2002 by ISO 9001 certification and in 2004, the company was inspected in 2004 by the National Agency of Drug Safety (ANSM) to become compliant according to Good Laboratory Practice (GLP). With a strong focus on business development and with the assistance of regional investors, Clean Cells grew steadily. This led to the opening of new production sites to become a pharmaceutical establishment in May 2014.
In recent years, Clean Cells continued its reputation and strengthened its position on the French market. In order to increase its international position, the founders created a business unit to forge new opportunities in Europe, the United States and Asia.
Today, Clean Cells offers a comprehensive service portfolio ranging from test for viral and biological safety of biopharmaceuticals, the production of cell and virus banks that are GMP grade and secure storage, as well as the production of experimental drugs such as cell therapy products and therapeutic phages. Clean Cells aims to become a major role in the development of new therapies to revolutionize personalized medicine.
Clean Cells through the years
2019 and after
New CDMO facility, acquisition of Naobios, extension of QC portfolio…
+ 35% Sales
New Investors (Archimed)
Creation of Clean Biologics
New process development platform
(+) 50% Sales
(+) 50% Staff
(+) 30% Lab space
Production and Characterization
of ATMPs (eg: hESCs, iPS,…)
Opening of the « Etablissement Phamaceutique »
Phase II clinical Batch production and GMP certification (phagotherapy)
Creation of Clean Cells
Development QC Portfolio
Opening of BSL3 lab and GMP compliance
Opening of 4 Cgmp suites